13F filer · CIK 1953107
ENAVATE SCIENCES GP, LLC
New York, NY · filing since Q4 2024 · last filing Aug 14, 2026
Reported value
$345.4M
$-6.1M vs prior
Positions
7
New / sold out
0 / 0
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $3.3M
Top-10 weight
100.0%
Biggest buys vs Q1 2026
No new or increased positions this quarter.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | CAMP4 THERAPEUTICS CORP | -765,379 | -34.9% | $-3.3M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | SIONNA THERAPEUTICS INCCOM | 2,478,030 | $109.0M | 31.56% |
| 2 | ZENAS BIOPHARMA INCCOM | 3,919,159 | $99.5M | 28.80% |
| 3 | IMMUNOME INCCOM | 3,613,799 | $76.6M | 22.17% |
| 4 | BRIDGEBIO ONCOLOGY THERAPEUTCOM NEW | 2,626,946 | $20.0M | 5.80% |
| 5 | COMPASS THERAPEUTICS INCCOM | 7,788,150 | $17.1M | 4.94% |
| 6 | UPSTREAM BIO INCCOM | 2,459,703 | $17.0M | 4.93% |
| 7 | CAMP4 THERAPEUTICS CORPCOM | 1,425,541 | $6.2M | 1.80% |